This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. NRSN, FBLG, RANI, FGEN, SXTC, COEP, PULM, MRNS, INKT, and DYAIShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include NeuroSense Therapeutics (NRSN), FibroBiologics (FBLG), Rani Therapeutics (RANI), FibroGen (FGEN), China SXT Pharmaceuticals (SXTC), Coeptis Therapeutics (COEP), Pulmatrix (PULM), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors NeuroSense Therapeutics FibroBiologics Rani Therapeutics FibroGen China SXT Pharmaceuticals Coeptis Therapeutics Pulmatrix Marinus Pharmaceuticals MiNK Therapeutics Dyadic International NeuroSense Therapeutics (NASDAQ:NRSN) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Does the media refer more to NRSN or TENK? In the previous week, NeuroSense Therapeutics had 1 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for TenX Keane Acquisition. NeuroSense Therapeutics' average media sentiment score of 1.89 beat TenX Keane Acquisition's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Overall Sentiment NeuroSense Therapeutics Very Positive TenX Keane Acquisition Neutral Is NRSN or TENK more profitable? Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -590.79% TenX Keane Acquisition N/A N/A N/A Do analysts prefer NRSN or TENK? NeuroSense Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 488.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of NRSN or TENK? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer NRSN or TENK? NeuroSense Therapeutics received 4 more outperform votes than TenX Keane Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformNeuroSense TherapeuticsOutperform Votes480.00% Underperform Votes120.00% TenX Keane AcquisitionN/AN/A Which has preferable earnings & valuation, NRSN or TENK? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$11.28M-$0.54-4.41TenX Keane AcquisitionN/AN/AN/AN/AN/A SummaryNeuroSense Therapeutics beats TenX Keane Acquisition on 8 of the 10 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$9.78M$482.13M$2.55B$8.52BDividend YieldN/A7.68%13.02%4.17%P/E RatioN/A2.5011.6819.65Price / SalesN/A80.163,130,854.81152.07Price / CashN/A69.0161.1334.64Price / BookN/A6.283.774.59Net IncomeN/A$35.76M-$466.93M$248.23M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$1.47flatN/A-87.0%$9.78MN/A0.00N/AGap UpNRSNNeuroSense Therapeutics2.5029 of 5 stars$2.49+16.9%$14.00+462.2%+145.4%$34.03MN/A-3.8910Positive NewsGap UpHigh Trading VolumeFBLGFibroBiologics3.1033 of 5 stars$0.87-7.1%$13.00+1,394.3%-88.6%$33.29MN/A-4.1410RANIRani Therapeutics2.1052 of 5 stars$0.57-1.7%$9.40+1,541.3%-87.0%$32.92M$1.20M-0.54110Positive NewsFGENFibroGen4.5481 of 5 stars$0.31-0.1%$10.00+3,136.2%-76.4%$31.22M$7.00M-0.25570Stock SplitGap DownSXTCChina SXT Pharmaceuticals0.3711 of 5 stars$1.95-7.6%N/A-79.2%$30.87M$1.82M0.0090Short Interest ↑Gap DownCOEPCoeptis Therapeutics1.351 of 5 stars$8.67-5.1%N/A+27.1%$30.47M$62.87K-1.492Positive NewsPULMPulmatrix0.4002 of 5 stars$8.32-1.5%N/A+307.3%$30.37M$1.92M-3.1520MRNSMarinus Pharmaceuticals2.1489 of 5 stars$0.55-0.2%$4.79+771.6%-62.5%$30.32M$30.99M-0.22110INKTMiNK Therapeutics3.1124 of 5 stars$7.59+0.1%$37.50+394.1%-20.5%$30.25MN/A-1.9530Short Interest ↓Gap DownDYAIDyadic International2.2005 of 5 stars$1.00+1.0%$6.00+500.0%-54.8%$30.09M$3.34M-4.357Positive NewsGap Up Related Companies and Tools Related Companies NRSN Alternatives FBLG Alternatives RANI Alternatives FGEN Alternatives SXTC Alternatives COEP Alternatives PULM Alternatives MRNS Alternatives INKT Alternatives DYAI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
